Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)
ID: 357008Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357008

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-146.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)" aimed at supporting innovative research into the mechanisms underlying structural birth defects. This initiative encourages applicants to utilize advancements in genetics, omics methods, and synthetic biology to explore genetic, environmental, and epigenetic factors contributing to these anomalies, which affect approximately 3% of live births in the U.S. The grant allows for budgets up to $499,999 in direct costs per year, with project periods not exceeding five years, and applications are due by February 5, 2025. Interested parties can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-146-Full-Announcement.html
    PAR-25-146.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has issued a funding opportunity titled "Advancing Research to Understand Congenital Malformations" (R01 Clinical Trial Not Allowed). This initiative aims to support research that explores the mechanisms behind structural birth defects using animal models and translational approaches. Researchers are encouraged to leverage advancements in genetics, omics methods, and synthetic biology to investigate genetic, environmental, and epigenetic interactions contributing to these defects. Key dates include an application opening on January 5, 2025, with a submission deadline of February 5, 2025. The grant allows budgets up to $499,999 in direct costs per year, with project periods not exceeding five years. Eligible applicants encompass various organizations, including higher education institutions and nonprofits. The document emphasizes the importance of innovative research to identify causes and develop prevention and treatment strategies for congenital anomalies, which affect approximately 3% of live births in the U.S. NICHD aims to foster collaboration among researchers to enhance understanding and interventions for structural birth defects, ultimately impacting public health and socioeconomic factors. A comprehensive sharing plan for data and biospecimens is also mandated to promote scientific collaboration.
    Similar Opportunities
    Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)" aimed at expanding knowledge of disorders that are currently or may become part of statewide newborn screening programs. This initiative seeks to gather comprehensive data on the natural history of these conditions to facilitate appropriate interventions for affected infants, improve diagnostic accuracy, and support the development of targeted treatments. The funding will assist in identifying biological mechanisms, understanding genetic diversity, and establishing data collection systems for longitudinal studies, emphasizing the importance of research in newborn screening. Interested applicants, including various educational and community organizations, can submit proposals with a maximum project period of five years, with the funding cycle opening on January 5, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-227.html.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)" aimed at promoting research and development of novel screening methods and therapeutic interventions for conditions identified through newborn screening. This initiative encourages innovative projects that generate preliminary data on both existing and potentially fatal genetic disorders, emphasizing the importance of early detection and intervention. The program is open to a wide range of eligible applicants, including higher education institutions, nonprofits, and governmental bodies, with a total funding ceiling of $275,000 over two years. Interested applicants should note that the submission deadlines begin on January 16, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for in-depth phenotyping and research using knockout mouse strains that exhibit embryonic or perinatal lethality or subviability, under the R01 Clinical Trial Not Allowed grant mechanism. This initiative aims to encourage applications that leverage the International Mouse Phenotyping Consortium (IMPC) resources to better understand genetic functions related to congenital diseases and structural defects, particularly those affecting embryonic development and fertility. The program is part of a broader effort to catalog mammalian gene function, with an award ceiling of $499,999 per year for projects lasting up to five years. Interested applicants must submit their proposals by January 7, 2026, and can find additional information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity aimed at developing novel theories and methods for understanding the genetic architecture of complex human traits through the R21 Exploratory/Developmental Research Grant mechanism. This initiative seeks interdisciplinary applications that address the interplay of genetic and non-genetic factors influencing trait variation, emphasizing the use of large-scale datasets and innovative approaches from various scientific fields. The grant allows for a maximum budget of $275,000 over two years, with a prohibition on clinical trials and a limit on new data generation to 20% of project costs. Interested applicants should note that proposals are due by January 7, 2027, and can direct inquiries to grantsinfo@nih.gov for further information.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns," aimed at advancing research in novel screening methods and therapeutic interventions for genetic conditions identified through newborn screening. This initiative encourages the development of innovative screening assays, the use of artificial intelligence, and the exploration of socio-economic implications related to newborn screening, with a focus on conditions that may benefit from early detection and treatment. The grant supports long-term research projects (R01) and is open to a diverse range of applicants, including higher education institutions and community-based organizations, with applications accepted until November 16, 2027. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-265.html.
    Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)" aimed at supporting clinical projects that enhance readiness for clinical trials in rare diseases. This initiative seeks applications that focus on developing and testing biomarkers and clinical outcome measures, as well as defining the characteristics of rare diseases to facilitate the design of future clinical trials. The program is particularly important for addressing the needs of rare diseases affecting fewer than 200,000 individuals in the U.S., with a maximum budget of $275,000 for direct costs over a project period of up to two years. Interested applicants can find more information and submit inquiries via email to grantsinfo@nih.gov, with the application deadline set for July 20, 2028.
    Developing novel theory and methods for understanding the genetic architecture of complex human traits (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Developing novel theory and methods for understanding the genetic architecture of complex human traits" under the R01 Clinical Trial Not Allowed grant program. This initiative aims to support interdisciplinary research that enhances the understanding of how genetic and non-genetic factors contribute to complex trait variation among individuals and populations, encouraging innovative theoretical approaches and the use of large-scale datasets. The program is significant for advancing genetic research, addressing health disparities, and promoting collaborative research environments. Interested applicants, including higher education institutions and non-profits, must submit their applications by February 5, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-23-302.html.
    Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Exploratory/Developmental Research Grant to develop novel theories and methodologies for understanding the genetic architecture of complex human traits. The objective is to support innovative research that explores both genetic and non-genetic factors influencing trait variation across biological, social, and ecological levels, with a particular emphasis on addressing cancer disparities and employing systems epidemiology modeling. This grant allows for a budget of up to $275,000 over a two-year period, and applications are open to a diverse range of organizations, including higher education institutions and nonprofits. Interested applicants can find more information and submit their proposals by the close date of January 7, 2027, and may contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders" (PAR-25-327), aimed at supporting Investigational New Drug (IND)-enabling studies and preparations for First-in-Human (FIH) clinical trials. This initiative focuses on advancing innovative gene-based therapies, such as oligonucleotides and viral vector approaches, for ultra-rare disorders affecting fewer than 6,000 patients, with an emphasis on projects that demonstrate robust proof of concept data and readiness for clinical trials. Eligible applicants include a wide range of organizations, including higher education institutions and various nonprofit and for-profit entities, with applications requiring detailed project planning and compliance with Good Manufacturing Practices (GMP). The application period opens on January 9, 2025, with a close date of October 8, 2027, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    GREGoRi Innovation Projects (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to announce a funding opportunity titled "GREGoRi Innovation Projects (U01 Clinical Trial Optional)" aimed at soliciting applications for research on proof of concept studies that explore innovative strategies for identifying genes or variants associated with rare genetic disorders. This initiative seeks to advance beyond traditional DNA sequencing methods by incorporating emerging molecular technologies, such as multi-omics and RNA-seq, to enhance the understanding of these disorders. The funding will be provided through a cooperative agreement, with no cost-sharing requirement, and is particularly targeted at small businesses engaged in health-related research. Interested applicants should prepare for the anticipated Notice of Funding Opportunity (NOFO) publication in 2025, with applications due in 2026, and can reach out to Lisa H. Chadwick at lisa.chadwick@nih.gov or by phone at 301-435-7275 for further information.